Evidence map›Paper›PMID 33680874›Full record

ReviewWorld journal of clinical oncology2021

New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging.

Celeste Manfredi, Esaú Fernández-Pascual, Estefanía Linares-Espinós, Felipe Couñago, Juan Ignacio Martínez-Salamanca

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025
    Review
  3. Article
  4. A Canadian center's experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Celeste ManfrediDepartment of Woman, Child and General and Specialized Surgery, Urology Unit, University of Campania "Luigi Vanvitelli", Naples 81110, Italy.
Esaú Fernández-PascualDepartment of Urology, Hospital Universitario La Paz, Madrid 28046, Spain.
Estefanía Linares-EspinósDepartment of Urology, Hospital Universitario La Paz, Madrid 28046, Spain.
Felipe CouñagoRadiation Oncology, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón 28223, Madrid, Spain.
Juan Ignacio Martínez-SalamancaLYX Institute of Urology, Facultad de Medicina, Universidad Francisco de Vitoria, Pozuelo de Alarcón 28223, Madrid, Spain.
Hospital Universitario La Paz · ESHospital Universitario Quirónsalud Madrid · ESUniversidad Francisco de Vitoria · ESUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imaging has a central role in the context of focal therapy (FT) for prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) is a novel imaging modality that combines the morpho-functional information of MRI with the molecular characterization of PET

Indexed as

CryotherapyFocal therapyHigh-intensity focused ultrasoundPositron emission tomography/magnetic resonance imagingProstate cancerProstate-specific membrane antigen

Identifiers

PMID33680874
PMCPMC7918526
OpenAlexW3133343499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.